Positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery announced by Samsara Vision

News
Article

Results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively.

Samsara Vision publishes positive imtermediate-term visual and safety outcomes of SING IMT - Image credit: Adobe Stock / ©Photocreo Bednarek

(Image credit: Adobe Stock / ©Photocreo Bednarek)

Samsara Vision has reported intermediate-term visual and safety outcomes of the SING IMT (Smaller-Incision New-Generation Implantable Miniature Telescope) in patients 6 months post-surgery. According to the company, SING IMT implantation improved distance and near vision, with a low impact on the corneal endothelium cell density and manageable safety outcomes.

Furthermore, results showed that at 6 months post-surgery, at least 1-, 2-, and 3-line gains in best-corrected distance were achieved in 97.1%, 68.6%, and 51.4% of operated eyes, respectively. The percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months, with distance vision also being improved by ⁓3 lines at 6 months post-surgery.

The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD). Starting 6 weeks after surgery, patients participated in a required rehabilitation program, attending 8 90-minute sessions every 2-to-3 weeks for 6 months to optimize their visual outcomes.

No clinically meaningful change from baseline was measured in intraocular pressure or anterior chamber depth. The mean (SD) change from baseline in corneal endothelial cell density at 6 months in operated eyes was -280.7 (315.9) cells/mm2 (-11.4 %).

"This 6-month review highlights the potential of SING IMT to restore meaningful vision to individuals blinded by AMD, while preserving long-term corneal health with its innovative design," said Prof. Toro, co-author of the study from University Hospital Federico II, Naples, Italy.

The SING MT is approved for use in CE Mark referenced countries, with 19 CE referenced countries having implanted the SING IMT in more than 400 patients.

References
Samsara Vision Announces Positive Six-Month Visual and Safety Outcomes from the SING IMT® (Smaller-Incision New-Generation Implantable Miniature Telescope). Press Release. Published January 13, 2025. Accessed January 13, 2025. https://www.businesswire.com/news/home/20250112004584/en/Samsara-Vision-Announces-Positive-Six-Month-Visual-and-Safety-Outcomes-from-the-SING-IMT%C2%AE-Smaller-Incision-New-Generation-Implantable-Miniature-Telescope

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
© 2025 MJH Life Sciences

All rights reserved.